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Hepatitis B virus (HBV) and hepatitis C virus (HCV) 
are hepatotropic, non-cytopathic viruses able to estab-
lish a persistent infection that causes different degrees of 
hepatic inflammation (chronic hepatitis), leading to the 
development of liver cir rho sis and hepatocellular carci-
noma (HCC) (Caccamo et al. 2014; Easterbrook et al. 
2017). Today, the main goal of HBV therapy is to prevent 
the progression of the disease, improving survival and 
the quality of life; whereas, for the HCV therapy, the aim 
is to cure the infection to achieve a sustained virological 
response and consequently, to prevent HCC develop-
ment (Akhan et al. 2015). Additionally, viral load (VL) 
monitoring is important in assessing the therapeutic 
response, monitoring treatment success and detect-
ing drug-resistant viruses (Singh et al. 2017). There are 
several commercially available HBV-HCV monitoring 
assays which are mainly based on real-time polymerase 
chain reaction (RT-PCR); but, using the most effective, 
the cheapest and the fastest detecting system plays an 
important role in diagnosing viral infections. Although 
these techniques are preferred due to their excellent 
analytical sensitivity, specificity, accuracy, and broad 
dynamic range of linear quantification, they require 
many steps and consumables in the qualified laborato-
ries (Portilho et al. 2015; Wu et al. 2017). VL assays also 
need to be batched as they arrive in the laboratory. Even 
a small change in the efficiency of the amplification can 
lead to striking differences in the amount final product. 
These reasons indicate the necessity of inventing fully 
standardized, reproducible and sensitive new assays for 
monitoring of HBV and HCV infections.
The aim of the study was to compare the analy- 
 tical performance of random access testing (Beckman 
Coulter DxN VERIS) with routine diagnostic PCR kit 
(artus Qiagen).
A total of 67 chronic hepatitis B (CHB) patients with 
genotype D and 44 chronic hepatitis C (CHC) patients 
infected with genotype 1b from Kocaeli province in 
Marmara region of Turkey were analyzed in paral-
lel with the use of DxN VERIS and Qiagen systems 
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A b s t r a c t
The Beckman Coulter DxN VERIS system is a fully automated, closed molecular diagnostic instrument for viral load quantification of 
hepatitis B virus and hepatitis C virus. In this study, the analytical performance of this new system was compared to routine diagnostic 
Qiagen PCR kit by using the same clinical samples. The DxN VERIS system demonstrated a high analytical performance. The DxN VERIS 
allows random access, which means that samples can be uploaded straight on to the system at any time; so, it provides an improvement of 
workflow, staff productivity and allows faster turn-around of viral load results.
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synchronously. Qiagen HBV DNA and HCV RNA 
levels in the samples were in the range from negative 
to > 108 IU/ml and > 107 IU/ml, respectively, and they 
are displayed in Table  I. The PCR-negative samples 
were previously diagnosed as taken from the HBV and 
HCV carriers and their negativities were provided by 
antiviral treatment. The most predominant genotypes 
in Turkey are HBV genotype D and HCV genotype 
1b; therefore, we have only involved these genotypes 
in our study (Karatas et al. 2018). The selected blood 
samples were immediately centrifuged, aliquoted, and 
then, stored at –80°C until use. The diagnosis of chronic 
hepatitis B and C was made on the basis of biochemi-
cal, serological, virological and histological data accord-
ing to the EASL guidelines (EASL 2017a, 2017b). The 
samples were analyzed by using both fully automated 
DxN VERIS kits (Beckman Coulter DxN VERIS HBV/
HCV kits, Nyon, Switzerland) and Qiagen kits (artus 
HBV/HCV QS RGQ kit, Qiagen, Hilden, Germany) on 
the same day according to the manufacturer’s recom-
mendations. DxN VERIS HBV/HCV assays have quan-
tification ranges from 10–109 IU/ml and 12–108 IU/ml, 
respectively as it is stated in the package inserts. The 
relationship between VL quantifications measured by 
both DxN VERIS and Qiagen assays were analyzed by 
Passing-Bablok (PB) regression method. Bland Altman 
plot (BAP) design was used to calculate statistical 
limits, correlation and standard deviation (SD) of the 
differences between two types of measurement. To 
control the distribution of the differences and other 
properties between quantitative values, a graphical 
approach was used. Statistical analysis of the study was 
made with the Analyse-it Software program (Analyse-it 
Ltd. v 4.60, Microsoft Corp. Leeds, UK).
According to HBV BAP (DxN VERIS combined 
Qiagen HBV log IU/ml), the specificity resulted in 
95% LoA (limits of agreement) [CL (confidence level) 
95% = –1.59–0.61], the correlation was equal to 0.97 
with SD 0.55 and a mean SD = –0.47. HBV PB indica- 
ted DxN VERIS combined = –1.179 + 1.153 Qiagen 
log IU/ml with the correlation equal to 0.97. HBV plots 
for PB and BAP are shown in Fig. 1.
For HCV analysis, BAP (DxN VERIS combined 
Qiagen HCV log IU/ml) illustrated the specificity of 
95% LoA (CL 95% = –1.59–0.72), the correlation of 0.90 
with SD 0.59 and a mean SD = –0.43. HCV PB analysis 
indicated DxN VERIS combined = –0.3394 + 0.8602 
Qiagen log IU/ml with the correlation of 0.90. HCV 
plots for PB and BAP are shown in Fig. 2.
Viral nucleic acid detection is the gold standard 
for the detection of viral genomes in clinical samples. 
COBAS Ampliprep, artus Qiagen and Abbott real-time 
PCR assays are currently the most frequently used 
platforms worldwide in this field. DxN VERIS systems 
were mainly compared to COBAS and Abbott systems 
rather than to Qiagen kits (Saune et al. 2016; Patrick 
et al. 2017; Park et al. 2019). Studies comparing DxN 
VERIS HBV to Roche HBV and to Abbott real-time 
HBV illustrate the average bias that was determined as 
being equal to –0.26 (95% Cl: –0.37 to –0.15) and –0.36 
(95% Cl: –0.43 to –0.29), respectively in BAP. This was 
equal to –0.32 log IU/ml in another study (Robert et al. 
2014), and respectively to –0.47 log IU/ml in our study 
(Williams et al. 2014; Park et al. 2019). In the present 
study, we compared DxN VERIS with Qiagen HBV and 
HCV and their clinical performances displayed a strong 
correlation (95%) similar to one another study (Micheli 
et al. 2016). Currently, the main therapy is based on 
Peg-IFN and nucleos(t)ide analogues for CHB. How-
ever, the main clinical challenge is the development of 
antiviral resistance, since long-term therapeutic regi-
mens are given to the majority of these patients (EASL 
2017b). While monitoring VL, HBV breakthrough 
that is demonstrated by a sudden increase in DNA 
level (from > 1 log10 IU/ml to > 1 × 105 IU/ml) can be 
observed (Braun et al. 2017). Early detection of such 
viral breakthrough is important because the analysis 
of the HBV gene mutations responsible for drug resist-
ance is a part of managing clinical treatment. The ran-
dom access testing can provide effective surveillance 
 Negative 12/67 (18%) Negative 11/44 (25%)
 < 101 14/67 (21%) > 101  1/44 (2%)
 > 102  9/67 (13%) > 102  1/44 (2%)
 > 103 13/67 (20%) > 104  2/44 (5%)
 > 104  4/67 (6%) >105  6/44 (14%)
 > 105  7/67 (10%) > 106 14/44 (32%)
 > 106  4/67 (6%) >107  9/44 (20%)
 > 108  4/67 (6%) –     –
Table I
The Qiagen HBV DNA and HCV RNA levels in sampling.
Pattern of HBV
sampling
HBV DNA (IU/ml),
n/total (%)
Pattern of HCV
sampling
HCV RNA (IU/ml),
n/total (%)
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for CHB treatment. Similarly, monitoring of HCV 
RNA during treatment is required to assess the suc-
cess of the treatment and to detect any breakthrough 
related to viral resistance. As the main goal of therapy 
for HCV is to cure the infection in order to prevent the 
development of HCC and complications related with 
HCV related liver diseases, random access system ena-
bles faster turn-around of VL results to physicians and 
allows early detection of possible resistance. Therefore, 
DxN VERIS system may be a new solution as it enables 
Fig. 1. HBV plots for Passing-Bablok (upper) and Bland Altman analysis (lower).
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same-day turn-around results to help the health system 
improving patient management. None of the other plat-
forms are true single-sample to answer and random-
access testing. This is the most important advantage of 
DxN VERIS system for us because medical reports can 
be transformed within a short time to different depart-
ments and physicians that could better manage the 
diseases with antiviral therapy in a short time.
Fig. 2. HCV plots for Passing-Bablok (upper) and Bland Altman analysis (lower).
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